734 / 1631
PROGRESSION-FREE SURVIVAL (ALL INHL PATIENTS):
ON STUDY VS. LAST PRIOR THERAPY
0
25
50
75
100
0
6
12
18
24
30
36
42
Patients at risk, n
125
60
33
22
12
4
125
40
14
9
5
2
1
Median PFS (months)
On study: 11.0
Last prior therapy: 4.6
PFS (%)
Time from start of idelalisib (months)
Gopal A
et al.
ASH 2014, Abstract #1708